[Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant]. / Aksolong: novaia bukkal'naia forma atsetilsalitsilovoi kisloty dlia primeneniia v kachestve antiagreganta.

AIM: Study of the tolerance and pharmacodynamic and pharmacokinetic characteristics of ascolong, a new buccal dosage form of aspirin containing a very low dose of acetylsalicylic acid (ASA): 12.5 mg. MATERIALS AND METHODS: The study was carried out in 43 healthy men (assessment of the drug tolerance) and 19 male patients with coronary disease or cerebrovascular disorders. In 10 patients the antiaggregant efficacy of ascolong administered once or regularly (for 2 weeks) in a dose of 12.5 mg was compared with placebo, in 9 patients a random cross study of 2-week courses of ascolong and Russian aspirin tablets in a dose of 100 mg was carried out. Platelet aggregation was assessed on days 1 and 14 of each course before and 2, 4, and 24 h after the drug intake. RESULTS: Ascolong containing a very low dose of ASA exerts a reliable antiaggregant effect after a single and regular intake, although this effect is less manifest than after aspirin tablets. Profiles of ASA concentrations in the blood were studied. Transbuccal entry of ASA in systemic circulation decelerated its metabolism into a less active metabolite, salicylic acid, due to which fact the ASA microdose had an expressed antiaggregant effect. The drug was sufficiently well tolerated. CONCLUSION: The new buccal film form of aspirin containing a very low dose of ASA possesses a good antiaggregant effect and is promising in subjects with contraindications to oral intake of aspirin.

[Kemantan treatment of patients with recurrent aphthous stomatitis]. / Lechenie kemantanom bol'nykh retsidiviruiushchim aftoznym stomatitom.

The authors assess the therapeutic efficacy of kemantan, an immunomodulator, used in the treatment of 30 patients with severe stubborn recurrent aphthous stomatitis (RAS). The blood immunological and biochemical characteristics were checked up over the course of treatment. Clinical and laboratory studies have shown that this immunocorrective agent is sufficiently effective for fibrous and cicatrizing RAS running a permanent course: the periods of the pathologic elements epithelialization are shortened, the permanent course of the condition is interrupted and the remissions are prolonged; clinical cure has been achieved in a number of cases. Kemantan is indicated for RAS patients only in cases with immunologic insufficiency, with immunologic responses monitored over the course of the treatment.